株式会社メディネット

予防医学に基づく新たな医療サービスの提供を目的として、東京都港区西新橋に株式会社メディネット（資本金1,000万円）を設立

Founded in Nishi-Shimbashi, Minato-ku, Tokyo, with the aim of providing a new medical support business in preventive medicine (capital:JPY10 million).

東京都世田谷区瀬田に分子免疫学研究所を開設、瀬田クリニック向けに細胞加工施設（瀬田CPC）を設置し、免疫細胞療法総合支援サービスを開始

Established Institute of Molecular Immunology in Seta, Setagaya-ku, Tokyo, constructed Cell Processing Center for Seta Clinic (Seta CPC), and started providing its core business Immuno-Cell Therapy Total Support Service.

東京都港区新橋に本社を移転

東京都港区新橋に本社を移転しました。

厚生労働省による新事業創出促進法に基づく「新事業分野開拓の実施に関する計画」の認定

Ministry of Health, Labour and Welfare approved 'Project for development of new business fields' under the Act for Facilitating the Creation of New Business.

Ministry of Health, Labour and Welfare approved "Project for development ofnew business fields" under the Act for Facilitating the Creation of New Business.

横浜市港北区新横浜に本社を移転、契約医療機関向けに細胞加工施設（新横浜CPC1）を設置し、免疫細胞療法総合支援サービスを開始

横浜市港北区新横浜に本社を移転し、新横浜CPC1を建設、契約医療機関に免疫細胞療法総合サポートサービスの提供を開始しました。

神奈川県横浜市港北区に先端医学研究所を開設

Established Institute of Medical Science at Kohoku-ku, Yokohama-shi, Kanagawa.

契約医療機関向けに細胞加工施設（新横浜CPC2）を増設

Established Shin-Yokohama CPC2 for contracted Medical Institutions.

東京都世田谷区玉川台に研究開発センターを新設、分子免疫学研究所と先端医学研究所を同センター内に移転し、先端医学研究所を「分子遺伝学研究所」に改称

Newly established Research and Development Center at Tamagawadai, Setagaya-ku, Tokyo. Transferred the Institute of Molecular Immunology and the Institute of Medical Science to the new institute, and renamed the latter to “Institute of Molecular Genetics.”

東京都世田谷区玉川台に研究開発センターを新設、分子免疫学研究所と先端医学研究所を同センター内に移転すると共に、先端医学研究所を「分子遺伝学研究所」に改称

大阪府吹田市江坂町に大阪事業所を開設、契約医療機関向けに細胞加工施設（大阪CPC）を設置し、免疫細胞療法総合支援サービスを開始

Established Osaka Office in Esaka-cho, Suita-shi, Osaka, constructed Osaka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.

Received 1st 'Courageous Management Award' sponsored by the Tokyo Chamber of Commerce and Industry.

Received 1st "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry.

Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. Shares listed on Tokyo Stock Exchange (Mothers: 2370).

Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. : MEDINET's shares were listed on Tokyo Stock Exchange (Mothers: 2370) (as of Oct. 8, 2003).

東京証券取引所マザーズ市場へ株式を上場

細胞医療支援事業においてISO9001の認証を取得

International Organization for Standardization certified ISO9001 Certification for quality management of cell culturing and processing.

「分子免疫学研究所」と「分子遺伝学研究所」を統合し、研究開発センターの名称を「先端医科学研究所」に改称

Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to 'Medinet Medical Institute.'

Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to "Medinet Medical Institute.".

日本初の治療用がん組織保管サービスである「自己がん組織バンク」サービスを開始

Started providing new cancer tissue storage service Self Cancer Cell Depository™.

東京大学医学部附属病院の22世紀医療センター内に免疫細胞治療学講座（免疫細胞治療部門）向けに細胞加工施設（東大22世紀医療センターCPC）を設置し、免疫細胞療法総合支援サービスを開始

Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the 'Department of Immunotherapeutics' established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital.

東京大学医学部附属病院の22世紀医療センター内に開設された「免疫細胞治療学講座（免疫細胞治療部門）」向けに細胞加工施設（東大22世紀医療センターCPC）を設置し、免疫細胞療法総合支援サービスを開始

Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the "Department of Immunotherapeutics" established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital.

独立行政法人国立病院機構大阪医療センターと免疫細胞療法の実施に対する技術支援を行うライセンス契約を締結

Concluded a license agreement with the National Hospital Organization Osaka Medical Center for immuno-cell therapy technological support at the center.

研究開発施設を東京都世田谷区の先端医科学研究所に統合し、名称を「研究開発センター」に改称

Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to 'Research and Development Center.'

Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to "Research and Development Center.".

株式会社医業経営研究所を設立

Established Institute of Medical Service Management, Inc.

九州大学先端医療イノベーションセンター向けに免疫細胞療法総合支援サービスを開始

Started Providing Immuno-Cell Therapy Total Support Service to Kyushu University's Center for Advanced Medical Innovation.

九州大学先端医療イノベーションセンターに共同研究部門「先進細胞治療学研究部門」を設置

Established the cooperative research department 'Department of Advanced Molecular and Cell Therapy' in Kyushu University Center for Advanced Medical Innovation.

Established the cooperative research department "Department of Advanced Molecular and Cell Therapy" in Kyushu University Center for Advanced Medical Innovation.

東大病院が実施する第3項先進医療（高度医療）に係る一部業務を受託

非小細胞肺癌患者における先進医療として自己γδTリンパ球を提供する東京大学病院へのサービス提供を開始しました。

NK細胞療法技術の提供開始

新規事業「細胞医療製品事業」に取り組む子会社「株式会社メドセル」設立

東京都品川区に再生・細胞医療用の細胞培養加工施設（品川CPF）を設置

Established a wholly owned subsidiary 'MEDcell Co., Ltd.', for the Cell Medicinal Product Business. For expansion of the 'Contract Cell Manufacturing Business,' established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF).

新規事業「細胞医療製品事業」に取り組む子会社「株式会社メドセル」設立 : 新規事業「細胞加工業」の拡大を目指し、東京都品川区に再生・細胞医療用の細胞培養加工施設（品川CPF）を設置

Established a wholly owned subsidiary "MEDcell Co., Ltd.", for the Cell Medicinal Product Business. For expansion of the "Contract Cell Manufacturing Business," established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF).

品川CPFの特定細胞加工物製造許可を取得

Obtained license for the manufacture of specified cell products in Shinagawa CPF.

東京都世田谷区の研究開発機能を本社に全面移転

東京都世田谷区玉川台から本社に研究開発機能を全面的に移転しました。

茨城県立こども病院の細胞加工業務を受託

Contracted cell processing business at Ibaraki Children's Hospital.

一般財団法人 健康医学協会と特定細胞加工物製造に関する契約を締結

Agreement with the Kenkoigaku Association on the manufacture of specified cell products.

新横浜細胞培養加工施設および大阪細胞培養加工施設の特定細胞加工物製造許可取得

見和中央クリニックと特定細胞加工物製造に関する契約を締結

Received regulatory approval to manufacture specified cell products at its Shin-Yokohama Cell Processing Center and Osaka Cell Processing Center.

Agreement with Miwa Central Clinic regarding manufacturing of specified cell products.

Histogenics社と自己培養軟骨「NeoCart®」のライセンス契約を締結

Entered into license agreement with Histogenics Corporation for Development and Commercialization of NeoCart for the Japanese Market.

独立行政法人国立病院機構と成人T細胞白血病を対象とした樹状細胞ワクチンの再生医療等製品としての製造販売承認取得を目的とした共同開発契約を締結

Concluded a joint development agreement with the National Hospital Organization with the goal of obtaining approval to manufacture and sell ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL).

With the National Hospital Organization concluded a joint development agreement with the goal of obtaining approval to manufacture and sell as a regenerative medicinal product ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL).

大阪細胞培養加工施設を新横浜細胞培養加工施設に統合、連結子会社株式会社医業経営研究所と株式会社メドセルの吸収合併契約締結（10月1日合併効力発生）

Integrated Osaka CPC into Shin-Yokohama CPC.

Conducted an absorption-type merger of two consolidated subsidiaries, Institute of Medical Service Management, Inc. and MEDcell Co., Ltd. The merger took effect on October 1, 2018.

株式会社JUNTEN BIOと再生医療等製品の製造技術の開発委受託契約締結

Signed a contract development agreement with JUNTEN BIO Co.,Ltd. for technology to manufacture regenerative medicinal products.

米国BioLegend社とライセンス契約を締結

Concluded a licensing agreement with BioLegend, Inc., headquartered in the US, for the development of research products using one of our novel monoclonal antibodies.

Concluded a licensing agreement with BioLegend, Inc., which is headquartered in the US, for the development of research products using one of our novel monoclonal antibodies.

新横浜細胞培養加工施設を品川細胞培養加工施設（品川CPF）に統合

Integrated Shin-Yokohama CPC into Shinagawa CPF.

東京都大田区平和島に本社を移転

東京都大田区平和島に本社を移転しました。

台湾Medigen Biotechnology Corp.へ当社γδT細胞培養加工技術のライセンス契約を締結

国立研究開発法人国立がん研究センターと共同研究契約を締結

Signed a licensing agreement with Taiwanese listed biopharmaceutical company Medigen Biotechnology Corp. regarding gamma-delta T cell culture technology.

Signed a joint research agreement with the National Cancer Center.

京都府公立大学法人京都府立医科大学と共同研究契約を締結並びに特許共同出願

国立大学法人九州大学と共同研究契約を締結

Signed a joint research agreement with the Kyoto Prefectural University of Medicine and patent joint application.

Signed a joint research agreement with National University Corporation Kyushu University.

品川CPFの再生医療等製品製造業許可を取得

Obtained license for the manufacture of regenerative medicinal products in Shinagawa CPF.

東京証券取引所の市場区分の見直しにより、東京証券取引所マザーズ市場からグロース市場に移行

Transitioned from Tokyo Stock Exchange Mothers market to Growth market due to the new market classification of the Tokyo Stock Exchange.

NKT細胞活性化樹状細胞加工技術の提供開始

Started providing processing technology for NKT cell-activated dendritic cells.